The Minimal Residual Disease Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Minimal Residual Disease Market?
The market size of the minimal residual disease has seen a quick expansion in the past few years. The market size was $1.78 billion in 2024, and it is predicted to grow to $2.01 billion in 2025. The compound annual growth rate (CAGR) is calculated to be 12.9%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Minimal Residual Disease Industry?
The market size for minimal residual disease is projected to reach $3.22 billion in 2029, growing at a compound annual growth rate (CAGR) of 12.5%.
Download Your Free Sample of the 2025 Minimal Residual Disease Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Minimal Residual Disease Market?
The key drivers in the minimal residual disease market are:
• Rise in the number of patients with cancer
• Increase in government awareness programs about cancer
• Growing healthcare affordability
• Advancements in next-generation sequencing technology
Global Market Segmentation: Identifying Major Minimal Residual Disease Industry Segments
The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
Pre-order the 2025 Minimal Residual Disease Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Minimal Residual Disease Market?
The key trends in the minimal residual disease market are:
• There is an increasing trend of advancements in next-generation sequencing technology.
• The standardization of Minimal Residual Disease (MRD) testing is seen as a significant new trend.
• The personalization of MRD monitoring is another emerging trend in the market.
• The development of liquid biopsy technologies and MRD-directed therapies are driving the future growth of the market.
Who Are the Top Competitors & Leading Players in the Minimal Residual Disease Market?
Major players in the minimal residual disease market are:
• Thermo Fisher Scientific Inc.
• Amgen Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Quest Diagnostics Incorporated
• Agilent Technologies Inc.
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• Exact Sciences Corporation
• Kite Pharma Inc.
• Natera Inc.
• Foundation Medicine Inc.
• NeoGenomics Inc.
• Guardant Health Inc.
• Grail LLC
• Tempus AI Inc.
• Veracyte Inc.
• Adaptive Biotechnologies Corporation
• Invivoscribe Inc.
• Mission Bio Inc.
• ArcherDx Inc.
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the minimal residual disease market in 2024
